Status of research and development of pediatric vaccines for Streptococcus pneumoniae

Vaccine

Volumn 34, Issue 26, 2016, Pages 2959-2961

  Alderson, Mark R ^a  

^a PATH   (United States)

Author keywords

Infant vaccination; Nasopharyngeal carriage; Pneumococcal conjugate vaccine; Protein vaccine; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; HUMAN; IMMUNIZATION; INFECTION PREVENTION; LOWEST INCOME GROUP; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN SUBUNIT; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; ANIMAL; CLINICAL TRIAL (TOPIC); MEDICAL RESEARCH; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL;

EID: 84970044515     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.107     Document Type: Article

References (13)

1. Liu L., Oza S., Hogan D., Perin J., Rudan I., Lawn J.E., et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 2014, 385(9966):430-440.
2. World Health Organization Estimated Hib and pneumococcal deaths for children under 5 years of age 2008, March 2012. http://www.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/index.html [accessed 21.08.13].
3. Drijkoningen J.J., Rohde G.G. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014, (Suppl. 5):45-51.
4. World Health Organization. http://www.who.int/biologicals/vaccines/pneumococcal/en/.
5. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
6. Song J.-H. Advances in pneumococcal antibiotic resistance. Expert Rev Respir Med 2013, 7(5):491-498.
7. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec (WER) 2007, 82(March (12)):93-104.
8. Waight P.A., Andrews N.J., Ladhani S.N., Sheppard C.L., Slack M.P.E., Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015, 15:535-543.
9. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
10. World Health Organization Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines-proposed replacement of TRS 927, Annex 2, ECBS, 19-23 October 2009 2010, http://www.who.int/biologicals/areas/vaccines/pneumo/Pneumo_final_23APRIL_.pdf.
11. Ginsburg A.S., Alderson M.R. New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today 2011, 47(3):207-214.
12. Brooks W.A., Chang L.J., Sheng X., Hopfer R. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study. Vaccine 2015, (July). PPR02 Study Team, pii:S0264-410X(15)00879-8.
13. Zhang F., Lu Y.J., Malley R. Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci U S A 2013, 110(August (33)):13564-13569.